Statement of Principles concerning leptospirosis (Reasonable Hypothesis) (No. 101 of 2022)

The core legal mechanism of this instrument is the Statement of Principles format, which sets out a set of factual factors that, when present and connected to relevant service, raise a “reasonable hypothesis” that a particular injury, disease or death is connected to service (s 9, s 10). The instrument defines the covered condition narrowly in clinical terms: leptospirosis is “an illness caused by infection with a bacterium from the genus Leptospira” (s 7(2)), with the note that clinical manifestations may include an initial flu‑like illness and complications such as renal failure and multi‑organ disease. For death, the instrument includes deaths “from a terminal event or condition that was contributed to by the person’s leptospirosis” (s 7(5)), and it defines “terminal event” by enumerating proximate or ultimate causes such as pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function (Schedule 1).

Temporal causation is expressed concretely. One primary factor that must exist is exposure to a pathogenic Leptospira between 2 and 30 days before clinical onset (s 9(1)). That establishes a discrete incubation window as a threshold for causal linkage. The other enumerated factor is inability to obtain appropriate clinical management for leptospirosis (s 9(2)), a factor that is expressly constrained by section 10(2) so it applies only to material contribution to, or aggravation of, leptospirosis where the disease was suffered or contracted before or during (but did not arise out of) the person’s relevant service.

The instrument supplies operational definitions for exposure and contact in Schedule 1. “Being exposed to a pathogenic bacterium” comprises several modes: an infected animal bite; direct contact of skin or mucous membranes with urine or tissues of infected animals, or with water, soil or vegetation contaminated with the bacterium; ingestion of contaminated food or water; and inhalation of contaminated aerosols (Schedule 1). “Direct contact” is defined as physical contact where no protective or impermeable barrier is used (Schedule 1). The Schedule also lists examples in a note, for instance pointing out that contamination of soil, water and vegetation can occur as a result of flooding and that contact with contaminated water can occur during outdoor activities such as swimming, wading and rafting in rivers, lakes and dams.

The instrument is framed to work within the VEA/MRCA claims architecture. It applies to claims that fall under the specific sections of those Acts cited in s 5. Where any factor in s 9 refers to an injury or disease that is the subject of another Statement of Principles, the other instrument’s factors apply in accordance with that instrument as in force from time to time (s 11). The Repatriation Medical Authority’s statement about sound medical‑scientific evidence is an express administrative rationale but is not itself elaborated in the instrument beyond that assertion (s 8).

This Statement of Principles affects three main actor groups: claimants (veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, and members under the MRCA) who seek to have leptospirosis or death from leptospirosis linked to relevant service in an entitlement claim; decision‑makers and administrators who apply Statements of Principles when assessing causation for claims under the specified provisions of the VEA and MRCA (s 5); and the Repatriation Medical Authority which authored the instrument and exercises the delegated power to determine Statements of Principles under subsection 196B(2) of the VEA (s 3, s 8).

For claimants, the instrument applies if their claim falls within the remit of section 120A of the VEA or section 338 of the MRCA (s 5). The Schedule’s definition of “relevant service” lists the kinds of service that bring a person into scope: operational service, peacekeeping service, hazardous service and British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1). The effect is that only persons whose service falls into one of these categories will have claims assessed against this Statement of Principles.

For decision‑makers, this instrument prescribes the causation factors to be considered when assessing whether a “reasonable hypothesis” exists linking leptospirosis to relevant service (s 9, s 10). The instrument therefore changes the evidentiary and evaluative framework used in adjudication: if a claimant can establish at least one of the factors in s 9 and show it is related to relevant service (s 10(1)), a reasonable hypothesis will have been raised.

For the Repatriation Medical Authority, the instrument is both an exercise of statutory power and an administrative statement of the Authority’s medical‑scientific view that leptospirosis can be related to relevant service (s 8). The Authority also determines definitions in the Schedule that constrain interpretation, such as what constitutes “being exposed to a pathogenic bacterium” and “direct contact” (Schedule 1). The instrument repeals the previous Statement of Principles No. 94 of 2014 (s 4), meaning that decisions after the commencement date will be based on the new terms.

Indirectly, parties who provide medical records, service records or environmental evidence may be affected because the instrument’s factors focus evidentiary collection on specific items: timing of exposure relative to onset (2-30 day window), records of exposure modalities (bitten by infected animal, direct contact with contaminated materials, ingestion, inhalation), and evidence regarding access to clinical management. The instrument’s definitions (for example, “direct contact” as contact without protective barriers) create practical points at which documentary proof or testimony will be relevant.

The Statement of Principles itself does not create positive duties such as reporting obligations or regulatory compliance activities; rather, it creates legal standards that claimants and decision‑makers must apply when assessing causation in relevant claims. The key rights implicated are claimants’ rights to have their claim assessed against the set of factors that the Repatriation Medical Authority has determined, and decision‑makers’ entitlement to apply those factors as the framework for raising a “reasonable hypothesis”.

Who decides: the Repatriation Medical Authority makes the Statement of Principles (s 3), and decision‑makers applying the VEA or MRCA provisions to claims will use the instrument’s factors. The Authority’s view that there is sound medical‑scientific evidence underpinning the instrument is stated as the basis for determining the factors (s 8). The instrument thereby confers on decision‑makers a defined evidentiary yardstick: at least one of the factors in s 9 must exist, and it must be related to relevant service (s 9, s 10(1)).

Claimant duties, in practical terms drawn from the instrument, include adducing evidence sufficient to establish one or more of the enumerated factors and evidence linking that factor to relevant service (s 9, s 10). For the exposure factor (s 9(1)), the claimant will need evidence that exposure to a pathogenic Leptospira occurred within the 2-30 day incubation window before clinical onset. For the clinical management factor (s 9(2)), the claimant must show inability to obtain appropriate clinical management; where that factor is relied upon in respect of material contribution or aggravation, the disease must have been suffered or contracted before or during,but not arising out of,the person’s relevant service (s 10(2)).

Decision‑maker duties include applying the definitions in the Schedule when interpreting exposure and contact modalities, for instance treating “direct contact” as contact without a protective barrier and applying the enumerated exposure pathways (Schedule 1). Decision‑makers must also account for cross‑references to other Statements of Principles: if a factor in s 9 refers to an injury or disease covered by another Statement of Principles, the other instrument’s factors apply in accordance with its terms as in force (s 11).

No penalties, offences or criminal sanctions are set out in the instrument itself; it is a standards document for causation assessment rather than an enforcement statute with penalties. The instrument repeals the prior Statement of Principles concerning leptospirosis and death from leptospirosis No. 94 of 2014, giving the Authority the continuing administrative responsibility to keep the Statements of Principles in alignment with medical‑scientific views (s 4).

The instrument contains no provisions that impose criminal sanctions, fines, or administrative penalties. It is not drafted as an enforcement instrument but as an evidentiary and definitional instrument to be used in the processing of entitlement claims under the VEA and MRCA (s 3, s 5). The effect of the instrument is therefore indirect: it shapes administrative outcomes in claims by setting the factual conditions that must be satisfied to raise a reasonable hypothesis that leptospirosis, or death from leptospirosis, is related to relevant service (s 9, s 10).

Enforcement in the conventional sense,investigatory powers, inspection rights or penalties for non‑compliance,is absent. Instead, the instrument is enforced through its application by decision‑makers to claims under the statutory frameworks cited in s 5. The instrument’s practical enforceability relies on adjudicative processes established by the VEA and MRCA, including the mechanisms for claim assessment, review and appeal that those Acts provide. The instrument itself does not prescribe those mechanisms; it specifies the medical‑factual thresholds to be applied within them.

Where a claimant’s evidence meets the instrument’s criteria, the probable administrative consequence is that a reasonable hypothesis will be regarded as raised, which in turn will affect entitlement decisions under the VEA or MRCA. Conversely, where a claimant cannot establish any of the factors in s 9 or cannot show the factor is related to relevant service (s 10(1)), decision‑makers may find the threshold for a reasonable hypothesis unmet. The instrument also allows reliance on factors in other Statements of Principles where a s 9 factor overlaps with an injury or disease already the subject of another Statement (s 11); that mechanism channels enforcement into the existing matrix of Statements of Principles.

Because the instrument is silent on penalties and procedural enforcement, risk of non‑compliance with the instrument per se is not a criminal or civil offence under the instrument. The risk is administrative: an unsuccessful claim or a denial of entitlement if the instrument’s requirements are not met. Any remedial avenues or review routes would be those provided by the VEA, the MRCA or other applicable administrative law mechanisms; this instrument does not specify appeal processes or remedies.

The Statement of Principles is explicitly integrative: it is made under subsection 196B(2) of the VEA (s 3) and applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s 5). It therefore functions as a subordinate, specialised instrument that guides causation assessments within the statutory frameworks of the VEA and MRCA. The instrument does not amend or repeal those Acts; it operates as an applied medical‑causal standard within the claims architecture those Acts create.

Section 11 creates a specific cross‑instrument interaction rule. If a factor in s 9 refers to an injury or disease already covered by another Statement of Principles determined under subsection 196B(2) of the VEA, then the factors in that other Statement of Principles apply as in force from time to time (s 11). This makes the instrument interoperable with the broader corpus of Statements of Principles: overlapping or linked conditions will be assessed according to the relevant Statements as currently in force, thereby avoiding inconsistent application where diseases have multiple contributing factors or where an exposure factor is more fully articulated elsewhere.

The instrument also references an external medical classification,the ICD‑10‑AM code A27,while clarifying that for the purpose of the Statement of Principles the meaning of leptospirosis is that given in subsection 7(2) (s 7(3)-(4)). By doing so, the instrument signals alignment with recognised clinical taxonomy but rejects an exclusive reliance on coding; the clinical definition controls application.

The Schedule’s definitions interact with ordinary evidentiary and factual determinations under the VEA and MRCA. For example, “being exposed to a pathogenic bacterium” is narrowly defined to include specific exposure modes (Schedule 1), and “direct contact” is defined as physical contact without a protective or impermeable barrier (Schedule 1). Those definitions will be used by decision‑makers when applying the VEA/MRCA standards for causation.

The instrument repeals the earlier Statement of Principles No. 94 of 2014 (s 4). That repeal is internal to the Statement‑of‑Principles framework and does not in itself amend the VEA or MRCA; it changes the body of medical standards that decision‑makers must apply post‑commencement.

Where the instrument interacts with other laws beyond the VEA and MRCA,for example, public health laws, workplace safety laws, or environmental regulation,no direct cross‑references are made in the text. Any operational or evidentiary overlap with external regulatory regimes will therefore be handled at the level of claims processing and evidence gathering, not by express statutory cross‑incorporation within this instrument.

This instrument expressly repeals the Statement of Principles concerning leptospirosis No. 94 of 2014 (Federal Register of Legislation No. F2014L01385) made under subsection 196B(2) of the VEA (s 4). The instrument itself is dated 21 October 2022 and commences on 21 November 2022 (s 1, s 2). The Repatriation Medical Authority affixed its Common Seal to the instrument at the direction of its Chairperson on the instrument’s date (instrument front matter). No further amendments, revisions or subsequent instruments are recorded within the text supplied.

The instrument does not include a schedule of amendments or a history of prior versions beyond the explicit repeal of the No. 94 instrument. It does not set out transitional provisions in the body of the text about whether claims lodged before commencement are to be assessed under the new or the repealed Statement of Principles; the instrument simply states it applies to claims to which certain sections of the VEA or MRCA apply (s 5) and that it commences on the stated date (s 2). The absence of transitional detail in the instrument means administration of pre‑commencement claims will depend on how the VEA/MRCA claims infrastructure, and administering agencies, treat repeal and replacement of Statements of Principles; that is outside the text of this instrument.

The instrument indicates that Statements of Principles are living administrative instruments determined under the authority in subsection 196B(2) of the VEA (s 3), which implies that the Authority may update or replace Statements as it revises its medical‑scientific view. The text also makes the provision in s 11 whereby other Statements of Principles operate “as in force from time to time”, indicating the compendium of Statements can change and that cross‑references will track those changes.

No amendments to the Schedule definitions are recorded other than those enacted by the repeal and replacement mechanism inherent in the instrument. The instrument itself is concise and self‑contained, replacing the prior Statement of Principles on the date of commencement. Any future amendment history would be recorded in subsequent instruments or in the Federal Register of Legislation but is not included in the supplied text.

The instrument contains no litigation history, judicial interpretations, or references to court decisions. It is a statutory administrative instrument , a Statement of Principles , determined by the Repatriation Medical Authority under the statutory power in subsection 196B(2) of the VEA (s 3). The text does not mention any cases, decisions, or litigation arising from either the current instrument or the instrument repealed by it (s 4). Therefore, there is no litigation history recorded within the document.

However, the instrument’s operative content creates areas where litigation or administrative review could conceivably arise in the claims context, because the instrument establishes precise factual thresholds and definitions that are to be applied by decision‑makers. Points that could be contested in litigation or review proceedings, derived from the instrument itself, include the interpretation and application of the temporal window set out in s 9(1) (exposure between 2 and 30 days before clinical onset), the meaning and evidentiary proof of “inability to obtain appropriate clinical management” in s 9(2) and the application limit set out in s 10(2), the assessment of whether an exposure was “related to the relevant service” (s 10(1)), and whether a death is properly characterised as “death from a terminal event or condition that was contributed to by the person’s leptospirosis” (s 7(5) and Schedule 1).

The instrument’s Schedule definitions could also be the subject of dispute. For instance, the definition of “direct contact” as physical contact without a protective or impermeable barrier (Schedule 1) may generate factual disputes about whether a barrier existed or whether a given contact qualifies under one of the enumerated exposure routes (Schedule 1). Cross‑instrument interaction under s 11, where a factor in s 9 refers to an injury or disease covered by another Statement of Principles, could generate legal argument about which Statement applies or about contemporary amendments to the referenced Statement.

Because the instrument does not itself set out procedures for claim review or judicial recourse, any litigation history would be external to it and would arise through the appellate or administrative review channels established by the VEA and MRCA and general administrative law. The instrument does not identify or limit those avenues; it is silent on remedies and does not record any prior litigation data.

The instrument contains a number of interpretative and evidentiary trapdoors that practitioners and claimants should note because they directly affect whether a reasonable hypothesis will be regarded as raised.

Temporal window: The exposure factor requires exposure to a pathogenic Leptospira between 2 and 30 days before the clinical onset of leptospirosis (s 9(1)). That is a tight, finite window which must align with clinical onset. If the claimant’s evidence of exposure is outside that window, the exposure factor in s 9(1) is not met. Practitioners should therefore map onset dates precisely and gather contemporaneous evidence that places exposure within the 2-30 day incubation window.

Narrow modes of exposure: “Being exposed to a pathogenic bacterium” is defined in specific modes only: a bite from an infected animal; direct contact of skin or mucous membranes with urine or tissues of infected animals or with contaminated water, soil or vegetation; ingestion of contaminated food or water; or inhalation of contaminated aerosols (Schedule 1). Evidence that does not match one of these modes may be excluded from consideration under s 9(1). The Schedule’s Note 1 does give examples such as flooding and outdoor water activities, but the operative definition remains the enumerated modes.

Protective barriers: “Direct contact” is defined as physical contact where no protective or impermeable barrier is used (Schedule 1). If a claimant had contact but used personal protective equipment, the “direct contact” pathway may not be satisfied. That detail can be decisive where the exposure relied upon was contact during work or training where protective clothing or gloves were available.

Clinical management factor constrained: The second factor,“inability to obtain appropriate clinical management for leptospirosis” (s 9(2)),is limited by s 10(2) to cases of material contribution to, or aggravation of, leptospirosis where the disease was suffered or contracted before or during (but did not arise out of) relevant service. That means the clinical‑management factor cannot be invoked to establish primary causation arising out of service; it only operates as a material contribution/aggravation factor in narrow temporal circumstances. Practitioners must therefore be careful about the sequencing of disease onset and service.

Death construction: Death from leptospirosis includes death “from a terminal event or condition that was contributed to by the person’s leptospirosis” (s 7(5)). The Schedule defines “terminal event” as proximate or ultimate causes including pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function. A practitioner must establish both contribution by leptospirosis and that the terminal event falls within the Schedule’s enumeration. Mere presence of leptospirosis at death is not automatically sufficient; contribution to the terminal event must be demonstrable.

ICD‑10‑AM code not determinative: Although subsection 7(3) notes that leptospirosis attracts ICD‑10‑AM code A27, subsection 7(3) also directs that “in applying this Statement of Principles the meaning of leptospirosis is that given in subsection 7(2)”. That means coded diagnoses may assist but do not displace the statutory clinical definition in s 7(2). Practitioners should ensure records and expert evidence align with the instrument’s clinical definition rather than relying solely on an ICD code.

Cross‑reference to other Statements: If a s 9 factor refers to an injury or disease covered by another Statement of Principles, the other Statement’s factors apply as in force from time to time (s 11). This can introduce complexity where multiple Statements overlap or where the other Statement has been amended. Practitioners must check the contemporaneous version of any referenced Statement.

No penalties or procedural detail: The instrument does not specify procedural steps, evidentiary standards, or appeals processes. It sets factual thresholds, leaving procedural enforcement, burden of proof allocation, and remedies to the VEA/MRCA statutory framework and administrative practice. Practitioners should not expect procedural guidance in this instrument.

Repeal and commencement timing: The instrument repeals the prior No. 94 instrument (s 4) and commences on 21 November 2022 (s 2). The instrument does not state whether or how pre‑commencement claims are to be treated; administrators and practitioners should be alert to how the VEA/MRCA system treats transitional claims.

Compliance in relation to this Statement of Principles means satisfying its factual thresholds so that a decision‑maker can properly conclude a reasonable hypothesis exists linking leptospirosis, or death from leptospirosis, to relevant service. The instrument itself sets out what must be proved and how certain terms are to be understood; compliance therefore requires (1) identifying the correct legal test under the VEA/MRCA and ensuring the claim falls within the sections cited in s 5, (2) assembling evidence to establish at least one factor in s 9, and (3) showing that the factor is related to the person’s relevant service (s 10(1)).

Step 1 - Establish that the claim is in scope: Confirm the claimant’s service type meets the Schedule’s definition of “relevant service” (Schedule 1) and that the claim is one to which section 120A of the VEA or section 338 of the MRCA applies (s 5). The instrument only applies where those statutory hooks are present.

Step 2 - Choose the operative factor and gather targeted evidence: The instrument requires at least one of the factors in s 9 to be established.

• For the exposure factor (s 9(1)), gather contemporaneous medical records documenting clinical onset dates, service records or incident reports indicating exposure events, witness statements where animals or contaminated water/soil contact occurred, environmental reports (for example showing flooding or contamination), and any laboratory or microbiological evidence indicating Leptospira infection. Ensure documentation places the exposure between 2 and 30 days prior to clinical onset; precisely date onset and exposure events because of the strict temporal window.

• For the clinical management factor (s 9(2)), document attempts to obtain care, evidence of denial, absence or inadequacy of treatment, timing of treatment relative to onset and service, and medical expert opinion on how lack of appropriate clinical management materially contributed to or aggravated the disease. If relying on s 9(2) for material contribution or aggravation, ensure the disease was suffered or contracted before or during (but did not arise out of) relevant service, as required by s 10(2).

Step 3 - Apply definitions from the Schedule: Use the Schedule definitions to frame evidence. For “being exposed to a pathogenic bacterium”, make sure the exposure narrative corresponds to one of the enumerated modes (infected animal bite; direct contact without a protective barrier with urine/tissues or contaminated water/soil/vegetation; ingestion; inhalation of aerosols) (Schedule 1). For “direct contact”, note whether protective or impermeable barriers were used; if such barriers were present, that pathway may not apply.

Step 4 - For deaths, link leptospirosis to the terminal event: If the claim concerns death, gather medical records, death certificates, autopsy or post‑mortem reports and expert opinions demonstrating that leptospirosis contributed to the terminal event or condition enumerated in the Schedule (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function) (s 7(5), Schedule 1). The claimant must establish contribution, not merely coincidence.

Step 5 - Cross‑check other Statements of Principles: If a s 9 factor overlaps with another Statement of Principles, identify and apply the other Statement as in force (s 11). Obtain and review that Statement for any different or additional factors and definitions.

Step 6 - Expert evidence and causation linkage: Because the instrument establishes medical‑causal thresholds, obtain qualified medical expert evidence that links the documented exposure or clinical management failure to the clinical onset of leptospirosis within the defined temporal parameters, and that links leptospirosis to any terminal event when relevant. Experts should reference the instrument’s definitions and the required timing.

Step 7 - Presentation and timing: Present evidence in the claim record in a structured way that maps directly to the instrument’s factors and definitions. Time lines that juxtapose service events, exposure events, onset dates and medical contacts will be useful given the instrument’s temporal focus.

Step 8 - Anticipate challenges: Be ready to address potential factual disputes as noted earlier: whether exposure fell within 2-30 days, whether contact was “direct” in the sense of the Schedule, whether protective equipment was used, whether appropriate clinical management was unavailable and how that unavailability materially affected outcome, and whether leptospirosis contributed to death. Prepare contemporaneous documentary and witness evidence to reduce reliance on retrospective assertions.

Step 9 - Administrative follow‑through: Because the instrument does not specify procedural mechanics, follow the VEA/MRCA claim lodgement, documentary and review procedures. If a cross‑referenced Statement is involved (s 11), also ensure that claim materials address any distinct requirements of that Statement.

By aligning evidence gathering and expert opinion directly with the instrument’s textual factors and Schedule definitions, claimants and advisers can make the most efficient and legally coherent presentation to decision‑makers who must apply this Statement of Principles in the determination of entitlement.